Daniel Macias, MD
Endocrinology, Diabetes & Metabolism · Huntington, WVNPI 1184734675
Payments from drug & device makers
Across 1,361 payments — averaging $503.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$447K
- Sanofi-aventis U.S. LLC$111K
- Boehringer Ingelheim$67K
- Novo Nordisk$57K
- Abbott$2K
- Dexcom, Inc.$729
- plus $2K from 16 others
What the payments were for
- Consulting fees$6,1751%
- Speaking & faculty fees$628,49992%
- Travel & lodging$35,5885%
- Food & beverage$15,3142%
- Education$2140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 789 | $447,000 |
| Sanofi-aventis U.S. LLC | 137 | $111,154 |
| Boehringer Ingelheim | 127 | $66,618 |
| Novo Nordisk | 125 | $56,576 |
| Abbott | 64 | $1,759 |
| Dexcom, Inc. | 13 | $729 |
| Johnson & Johnson | 40 | $368 |
| Novartis | 20 | $309 |
| Bayer | 7 | $297 |
| Medtronic(2 entities) | 3 | $242 |
| AstraZeneca | 12 | $198 |
| Insulet Corporation | 4 | $166 |
| AbbVie | 6 | $112 |
| Amarin Pharma, Inc. | 3 | $61 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Amgen | 2 | $37 |
| Globus Medical | 1 | $36 |
| Cequr Corporation | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Pfizer | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$185,735
- JARDIANCE$154,321
- MOUNJARO$126,050
- SOLIQUA 100/33$79,118
- TOUJEO$35,020
- RYBELSUS$27,997
- Ozempic$18,045
- Tresiba$7,407
- FREESTYLE LIBRE 3$757
- DEXCOM G6 TRANSMITTER$448
- Kerendia$250
- MINIMED 770G$225
- FreeStyle Libre$218
- Wegovy$124
- INVOKANA$123
- Omnipod$121
How this compares
$685,790 in reported general payments places this provider in the 95th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 1,017 | $1,238,273 |
| JardianceEmpagliflozin | 317 | $347,748 |
| TrulicityDulaglutide | 198 | $284,132 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 189 | $203,508 |
| OzempicSemaglutide | 168 | $197,688 |
| Tresiba Flextouch U-200Insulin Degludec | 112 | $159,102 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 102 | $104,392 |
| Tresiba Flextouch U-100Insulin Degludec | 153 | $99,929 |
| JanuviaSitagliptin Phosphate | 62 | $85,704 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 174 | $43,857 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $41,353 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 58 | $37,002 |
| Humalog Kwikpen U-100Insulin Lispro | 123 | $36,843 |
| Victoza 3-PakLiraglutide | 23 | $36,370 |
| Novolog FlexpenInsulin Aspart | 149 | $35,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $447,000 | $1,522,4051,215 claims |
| Boehringer IngelheimJardiance | $66,618 | $347,748317 claims |
| Novo NordiskOzempic, Novolog, Rybelsus | $56,576 | $226,804219 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $111,154 | $47,80151 claims |
| Johnson & JohnsonInvokana | $368 | $21,87128 claims |
| AbbVieSynthroid, Armour Thyroid | $112 | $14,252187 claims |
| AstraZenecaFarxiga | $198 | $13,70714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Huntington
- Ayman ElkadryHuntington$767K
- Henry DriscollHuntington$1K
- Mateen HotianaHuntington$1K
- John LeidyHuntington$864
- Ronald InnerfieldHuntington$833
- Sobia FaisalHuntington$705
- Henin AlsamarraieHuntington$695
- Nesreen BenhamedHuntington$526
- Maria Luzuriaga BassanteHuntington$421
- Muhammad HaqHuntington$280
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.